Litigation

Recent Posts

Supreme Court Says State Law Design Defect Claim For Generic Drug Is Preempted
Posted on 25 Jun 2013 by Tom Moylan

WASHINGTON, D.C. - (Mealey's) In a 5-4 decision, the U.S. Supreme Court on June 24 ruled that state law design defect claims that turn on the adequacy of a drug's warning are preempted by federal law ( Mutual Pharmaceutical Company, Inc. v. Karen... Read More

Supreme Court Questions If New Hampshire Law Escapes Preemption Of Drug Claims
Posted on 20 Mar 2013 by Tom Moylan

WASHINGTON, D.C. - (Mealey's) Several U.S. Supreme Court justices on March 19 questioned whether New Hampshire law allows a design defect claim against a generic drug manufacturer that escapes preemption under the high court's two drug preemption... Read More

U.S. High Court Allows Solicitor General To Argue For Drug Design Defect Preemption
Posted on 4 Mar 2013 by Tom Moylan

WASHINGTON, D.C. - (Mealey's) The U.S. solicitor general will be allowed to argue March 19 that design defect claims involving generic drugs are preempted by federal law, the U.S. Supreme Court decided March 4 in granting the federal government's... Read More